Real-life data demonstrate the potential of methotrexate in severe and moderately severe psoriasis.
First French guidelines for psoriasis therapy – subcutaneous MTX is First-Line.
Paris / Wedel (14 September 2018). Methotrexate (MTX) is established and proven as an effective systemic first-line therapeutic agent in the treatment of psoriasis.1 MTX is and remains the world’s most widely used systemic therapy, even despite new active substances entering the market. With the presentation of yet unpublished study data at the Medac-sponsored symposium, this year’s EADV Congress in Paris once again confirms the importance of methotrexate as the first-line treatment of moderately severe to severe psoriasis.